PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc. (OAPI) and Lundbeck today announced that the U.S. Food and Drug Administration (FDA) has expanded the label of ...
NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...
On Monday, May 7, during a poster session at the 2018 Annual Meeting of the American Psychiatric Association, researchers presented new data on the injectable antipsychotic treatment aripiprazole ...
According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
Otsuka America Pharmaceutical Inc. and Lundbeck said the FDA has approved the expanded label of Abilify Maintena® (aripiprazole) for extended-release injectable suspension. The new deltoid injection ...
PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...
In addition, ABILIFY is available in a 1 mg/mL nonrefrigerated Oral Solution and as a single-dose, ready-to-use solution for intramuscular injection 7.5 mg/mL. In adult patients, the recommended ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...
A long-acting, injectable form of the antipsychotic drug aripiprazole (Abilify, Otsuka) given once a month provides a safe and effective means of maintenance therapy for the treatment of bipolar I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback